In the clinic, cancers have already developed resistance to approved Src kinase inhibitors, primarily through their ability to activate a panel of survival kinases like ERK1/2, PI3K/Akt and mTOR (61–64), requiring the need for combinational therapies. Here, MTOR is linked to cancer.